Maternal Opioid Misuse (MOM) Model

The Maternal Opioid Misuse (MOM) Model addresses fragmentation in the care of pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD) through state-driven transformation of the delivery system surrounding this vulnerable population. By supporting the coordination of clinical care and the integration of other services critical for health, wellbeing, and recovery, the MOM Model aims  to improve quality of care and reduce costs for mothers and infants.

Select anywhere on the map below to view the interactive version
Source: Centers for Medicare & Medicaid Services

Highlights

  • Substance use is a leading cause of pregnancy-related death and can also contribute to preterm labor or other pregnancy and birth-related complications. Pregnant people with opioid use disorder (OUD), particularly those living in rural areas often lack access to health care during pregnancy and immediately after (postpartum). Many treatment programs do not accept pregnant clients and/or Medicaid beneficiaries. Maternity care providers often do not have the needed experience with substance use disorders to make evidence-based recommendations for treating OUD in pregnancy.
  • The Maternal Opioid Misuse (MOM) Model supports state-driven programs to improve the integration of maternity care with behavioral health and OUD treatment. In addition to providing integrated physical and behavioral health, MOM Model programs provide care coordination, and other supports to alleviate common barriers to care such as: transportation, childcare, and stigma around seeking treatment for opioid use disorder.
  • As a result of the comprehensive, integrated support the MOM Model is providing throughout pregnancy and the first postpartum year, mothers and their infants are expected to experience better quality care and improved health outcomes.

Background

The surge in substance use-related illness and death in recent years particularly affects pregnant women. In fact, substance use is now a leading cause of maternal death. Pregnant and postpartum women who misuse substances are at high risk for poor maternal outcomes, including preterm labor and complications related to delivery; and problems frequently exacerbated by malnourishment, interpersonal violence, and other health-related social needs. Infants exposed to opioids before birth also face negative outcomes, with a higher risk of being born preterm, having a low birth weight, and experiencing the effects of neonatal abstinence syndrome (NAS). In addition, Medicaid pays the largest portion of hospital charges for maternal substance use, as well as a majority of the $1.5 billion annual cost of NAS. Despite the significant and costly burden of maternal opioid misuse, numerous barriers impede the delivery of well-coordinated, high-quality care to pregnant and postpartum women with OUD, including:

  • Lack of access to comprehensive services during pregnancy and the postpartum period, even though state Medicaid programs may be able to provide the necessary coverage through state plan amendments or waivers.
  • Fragmented systems of care, which miss a critical opportunity to effectively treat women with OUD at a time when they may be especially engaged with the healthcare system.
  • Shortage of maternity care and substance use treatment providers for pregnant and postpartum women with OUD covered by Medicaid, especially in rural areas, where the opioid crisis is magnified.

Model Details

The goals of the MOM Model are to:

  • improve quality of care and reduce costs for pregnant and postpartum women with OUD as well as their infants;
  • expand access, service-delivery capacity, and infrastructure based on state-specific needs; and
  • create sustainable coverage and payment strategies that support ongoing coordination and integration of care.

These goals are achieved through a variety of approaches, including:

  • Fostering coordinated and integrated care delivery: Support the delivery of coordinated and integrated physical health care, behavioral health care, and critical wrap-around services.
  • Utilizing Innovation Center authorities and state flexibility: Leverage the use of existing Medicaid flexibility to pay for sustainable care for the model population.
  • Strengthening capacity and infrastructure: Invest in institutional and organizational capacity to address key challenges in the provision of coordinated and integrated care.

Funding

The CMS Center for Medicare and Medicaid Innovation (Innovation Center) will executed 10 cooperative agreements with states, whose Medicaid agencies will implement the model with one or more “care-delivery partners” in their communities.

The Notice of Funding Opportunity is no longer available. Applications must have been submitted by 3:00 p.m. EDT, May 6, 2019.

The state Medicaid agency and care-delivery partner(s) completed the application together. A maximum of $64.5 million was available for state awardees over the course of the five-year model.

CMS determined that, beginning July 1, 2021, the anti-kickback statute safe harbor for CMS-sponsored model patient incentives (42 CFR § 1001.952(ii)(2)) is available to protect MOM Beneficiary Incentives furnished in accordance with a CMS-approved Incentive Implementation Plan, provided that such MOM Beneficiary Incentives satisfy all safe harbor requirements set forth at 42 CFR § 1001.952(ii)(2) and the requirements of Section 29(c) of the Program Terms and Conditions.

Timeline

The MOM Model is a five-year period of performance with different types of funding. The implementation funding, transition funding, and opportunity for milestone funding are provided in three distinct model periods: Pre-implementation (Year 1), Transition (Year 2), and Full Implementation (Years 3-5).

Care delivery occurred in Year 2 of the model, the Transition Period. During this year, funding for care-delivery services that were not otherwise covered by Medicaid was provided by Innovation Center funds. The full Implementation Period began in year 3 of the model where states implemented their coverage and payment strategies. This overall structure sought to balance rapid model initiation and state flexibility, while minimizing administrative burden. In particular, the MOM Model design supports each awardee’s ability to quickly  deliver coordinated and integrated care to pregnant and postpartum women with OUD during the Transition Period, while supporting states to develop a long-term coverage and payment strategy that aligns with their state Medicaid program.

In spring 2020, CMS instituted a six-month postponement that MOM Model Recipients begin to screen and enroll beneficiaries by January 2021. The new date when awardees were required to begin to enroll MOM Model beneficiaries was July 1, 2021.

If you are interested in additional information about the Maternal Opioid Misuse (MOM) Model, please contact MOMmodel@cms.hhs.gov.

Evaluations

Latest Evaluation Report

Prior Evaluation Report

Additional Information

If you are interested in receiving updates and announcements about the MOM Model, please subscribe to the MOM Model listserv.


 

Where Health Care Innovation is Happening